Statins and mortality

Statins and mortality.

In this issue Simes et al. present pooled estimates for mortality from the Pravastatin Pooling Project (PPP). The two secondary prevention studies and the primary prevention trial included in the PPP enrolled together about 20 000 men and women aged 45–75 years with or without established coronary artery disease and a wide range of baseline lipid levels. As compared to placebo, in those allocat...

Statins and mortality among elderly patients hospitalized with heart failure.

BACKGROUND Small studies suggest that statins may improve mortality in patients with heart failure (HF). Whether these results are generalizable to a broader group of patients with HF remains unclear. Our objective was to evaluate the association between statin use and survival among a national sample of elderly patients hospitalized with HF. METHODS AND RESULTS A nationwide sample of 61 939 ...

Reducing morbidity and mortality in high risk patients with statins

Residual coronary heart disease remains a significant problem even after adequate statin therapy for cardiovascular risk reduction as currently recommended by the Adult Treatment Panel III (ATP-III) of the National Cholesterol Education Program (NCEP). This is particularly true for the high risk patients as defined by ATP-III that includes those patients who have a greater than 20% 10-year risk...

COPD and cancer mortality: the influence of statins.

BACKGROUND Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of lung cancer, independently of smoking. However, the relationship between COPD and total cancer mortality is less certain. A study was undertaken to investigate the association between COPD and total cancer mortality and to determine whether the use of statins, which have been associated with cancer r...

Mortality in prostate cancer and use of statins.